Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
出版年份 2022 全文链接
标题
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
作者
关键词
-
出版物
LANCET
Volume 401, Issue 10371, Pages 105-117
出版商
Elsevier BV
发表日期
2022-12-07
DOI
10.1016/s0140-6736(22)02420-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel
- (2022) Giampaolo Bianchini et al. Cancers
- 163O Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)
- (2022) G. Curigliano et al. ANNALS OF ONCOLOGY
- Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management
- (2022) Sandra M. Swain et al. CANCER TREATMENT REVIEWS
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- (2022) Javier Cortés et al. NEW ENGLAND JOURNAL OF MEDICINE
- PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03
- (2022) Seock-Ah Im et al. ANNALS OF ONCOLOGY
- Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)
- (2022) Yutaka Yamamoto et al. CANCER SCIENCE
- Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.
- (2022) Erika P. Hamilton et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
- (2022) C.A. Powell et al. ESMO Open
- Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
- (2021) Alice Indini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- (2021) A. Gennari et al. ANNALS OF ONCOLOGY
- Antibody–drug conjugates in breast cancer: the chemotherapy of the future?
- (2020) Eleonora Nicolò et al. CURRENT OPINION IN ONCOLOGY
- Antiemetics: ASCO Guideline Update
- (2020) Paul J. Hesketh et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
- (2020) Leisha A Emens et al. LANCET ONCOLOGY
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
- (2019) Kenji Tamura et al. LANCET ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
- (2017) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- (2016) Yusuke Ogitani et al. CANCER SCIENCE
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2013) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathobiology of chemotherapy-induced hair loss
- (2013) Ralf Paus et al. LANCET ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progression-Free Survival
- (2010) David Lebwohl et al. CANCER JOURNAL
- The Hazards of Hazard Ratios
- (2009) Miguel A. Hernán EPIDEMIOLOGY
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started